Cancer Biomarkers - Volume 15, issue 5

Authors: Gutiérrez-Monreal, Miguel A. | Villela, Luis | Baltazar, Severiano | Perfecto-Avalos, Yocanxochitl | Cardineau, Guy A. | Scott, Sean-Patrick

Article Type: Research Article

Abstract: BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma. Presently, one of the most important clinical predictors of survival in DLBCL patients is the International Prognostic Index (IPI). Circadian rhythms are the approximate 24 hour biological rhythms with more than 10 genes making up the molecular clock. OBJECTIVE: Determine if functional single nucleotide polymorphism in circadian genes may contribute to survival status in patients diagnosed with diffuse large B-cell lymphoma. METHODS: Sixteen high-risk non-synonymous polymorphisms in circadian genes (CLOCK, CRY2, CSNK1E, CSNK2A1, NPAS2, PER1, PER2, PER3, PPP2CA, and TIM) …were genotyped by screening PCR. Results were visualized by agarose gel electrophoresis and confirmed by two-direction sequencing. Clinical variables were compared between mutated and non-mutated groups. LogRank survival analysis and Kaplan-Meier method were used to calculate the overall survival. RESULTS: PER3 rs10462020 variant showed significant difference in overall survival between patients containing mutated genotypes and those with non-mutated genotypes (p = 0.047). LDH levels (p = 0.021) and IPI score (p < 0.001) also showed differences in overall survival. No clinical differences were observed in mutated vs. non-mutated patients. CONCLUSIONS: This work suggests a role of PER3 rs10462020 in predicting a prognosis in DLBCL overall survival of patients. Show more

Keywords: Circadian rhythm, single nucleotide polymorphism, diffuse large B-cell lymphoma, PER3, survival, biomarker

DOI: 10.3233/CBM-150511

Citation: Cancer Biomarkers, vol. 15, no. 5, pp. 699-705, 2015

Authors: Xia, Zongjiang | Duan, Fujiao | Jing, Chang | Guo, Zhihua | Nie, Changfu | Song, Chunhua

Article Type: Research Article

Abstract: BACKGROUND: DNA methyltransferase 3B (DNMT3B) has been discovered to play an important role in tumorigenesis. However, the association between DNMT3B -579G>T and the cancer risk has not been demonstrated. OBJECTIVE: The aim of this study is to provide a precise quantification for the association between DNMT3B -579G>T and the cancer susceptibility. METHODS: We performed a systematic literature review and assessed the methodological quality of included case-control designed studies based on Newcastle-Ottawa Scale (NOS). Pooled odds ratios (ORs) and corresponding 95% confidence intervals (95%CIs) were calculated to assess the strengths of the association. …RESULTS: We identified 18 studies for pooled analyses. Overall, the results demonstrated that the DNMT3B -579G>T polymorphism was significantly associated with a subtly decreased cancer risk (GT vs TT: OR = 0.78, 95%CI: 0.70-0.87, P< 0.01; GT + GG vs TT: OR = 0.81, 95%CI: 0.68-0.97, P= 0.02), especially in the Asian population and in colorectal cancer subgroup. In addition, when stratified for source of controls, the results of population-based subgroup showed the GT genotype might have a significantly decreased cancer risk, but not hospital-based subgroups. CONCLUSIONS: DNMT3B -579G>T polymorphism might contribute to the susceptibility of cancers especially in the Asian population and for colorectal cancer. Show more

Keywords: DNMT3B, polymorphism, cancer, quantitative assessment

DOI: 10.3233/CBM-150512

Citation: Cancer Biomarkers, vol. 15, no. 5, pp. 707-716, 2015